For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
DelveInsight's Hypofibrinogenemia- Epidemiology Forecast2030' report delivers an in-depth understanding of the Hypofibrinogenemia, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Hypofibrinogenemia Disease Understanding
Fibrinogen disorders are a set of hereditary or acquired abnormalities generally considered as rare conditions that are majorly classified as either qualitative (type II) or quantitative (type I). Qualitative fibrinogen disorder is a functional disorder that includes dysfibrinogenemia and hypodysfibrinogenemia.
Quantitative fibrinogen disorders, on the other hand, are characterized by the low amount of fibrinogen in the circulation and are further classified as hypofibrinogenemia, characterized by low fibrinogen levels. Generally, normal plasma fibrinogen levels are considered to range from 1.5 to 4.5 g/L; however, in hypofibrinogenaemia, plasma fibrinogen is reduced and characterized by fibrinogen levels lower than 1.5 g/L. In contrast, afibrinogenemia is an autosomal recessive disease, characterized by the complete deficiency of fibrinogen.
It is broadly classified into two types, i.e., Congenital Hypofibrinogenemia and Acquired Hypofibrinogenemia. Congenital fibrinogen disorders are caused by genetic variants occurring within all three fibrinogen genes. However, each gene (FGA, FGB, FGG) differently shows specific variants, wherein "nonsense" variants are mostly found within FGA, while FGG variants are prevalently responsible for missense changes.
In congenital hypofibrinogenemia, genes responsible for producing fibrinogen (a critical blood clotting factor) are unable to make a functional fibrinogen glycoprotein because of an inherited mutation. In contrast, acquired hypofibrinogenemia can result from either severe hepatic disease or disseminated intravascular coagulation (DIC), cardiac surgery, etc.
The Hypofibrinogenemia epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted Hypofibrinogenemia epidemiology segmented as the Total Cases of Hypofibrinogenemia, Type-Specific Cases of Hypofibrinogenemia (as congenital and acquired), and Acquired Hypofibrinogenemia cases. The report includes the Prevalent scenario of Hypofibrinogenemia symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
Country Wise- Hypofibrinogenemia Epidemiology
The epidemiology segment also provides the Hypofibrinogenemia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The total prevalent population of Hypofibrinogenemia Associated in 7MM countries estimated to be 11,084 cases in 2017.
- As per the estimates, the United States has the highest Prevalent population of Hypofibrinogenemia
- Among the EU5 countries, Germany had the highest prevalent population of Hypofibrinogenemia. On the other hand, Spain had the lowest prevalent population with 493 cases in 2017.
Scope of the Report
- Hypofibrinogenemia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
- Hypofibrinogenemia Epidemiology Report and Model provide an overview of the risk factors and global trends of Hypofibrinogenemia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
- The report provides insight into the historical and forecasted patient pool of Hypofibrinogenemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
- The report helps to recognize the growth opportunities in the 7MM concerning the patient population
- The report assesses the disease risk and burden and highlights the unmet needs of Hypofibrinogenemia
- The report provides the segmentation of the Hypofibrinogenemia epidemiology by Prevalent Cases of Hypofibrinogenemia in 7MM
- The report provides the segmentation of the Hypofibrinogenemia epidemiology by Type -specific Prevalent Cases of Hypofibrinogenemia in 7MM
- 11-Year Forecast of Hypofibrinogenemia epidemiology
- 7MM Coverage
- Total Prevalent Cases of Hypofibrinogenemia
- Prevalent Cases according to segmentation: Type-specific Prevalence of Hypofibrinogenemia, Acquired Hypofibrinogenemia cases
We interview KOLs, and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
- What will be the growth opportunities in the 7MM concerning the patient population about Hypofibrinogenemia?
- What are the key findings of Hypofibrinogenemia epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
- What would be the total number of patients of Hypofibrinogenemia across the 7MM during the forecast period (2017-2030)?
- Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
- At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
- What are the disease risk, burden, and unmet needs of Hypofibrinogenemia?
- What are the currently available treatments for Hypofibrinogenemia?
Reasons to buy
The Hypofibrinogenemia Epidemiology report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the global Hypofibrinogenemia market
- Quantify patient populations in the global Hypofibrinogenemia market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Hypofibrinogenemia therapeutics in each of the markets covered
- Understand the magnitude of Hypofibrinogenemia population by its Prevalence cases
- Understand the magnitude of Hypofibrinogenemia population by its Type-specific cases
- The Hypofibrinogenemia epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
- The Hypofibrinogenemia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2017-2030
The frequency of congenital fibrinogen disorders in the general population is very low. A North American Registry of Rare Bleeding Disorders has been successful in collecting valuable information on inherited fibrinogen disorders and other rare bleeding disorders. Among all the reported fibrinogen disorders in this registry, afibrinogenemia accounted for 24% of cases, hypofibrinogenemia accounted for 38%, and dysfibrinogenemia accounted for 38%.